BTK-IN-23

• UNSPSC Description:

  BTK-IN-23 is a BTK inhibitor (IC50: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC50s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997)[1].

• Target Antigen:

  Btk

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/btk-in-23.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C=CC(N1CCC[C@H](C1)N2N=C(C3=C(N=CN=C32)N)C4=C(C)C=C(C=C4C)OC5=CC=CC=C5)=O

• Molecular Weight:

  468.55

• References & Citations:

  [1]Sean T. Toenjes, et al. Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. ACS Med. Chem. Lett. 2023. https://doi.org/10.1021/acsmedchemlett.2c00523

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2573048-11-8